Kochujang, a Fermented Soybean-based Red Pepper Paste, Decreases Visceral Fat and Improves Blood Lipid Profiles in Overweight Adults

Study Overview
=================
Brief Summary
-----------------
With the epidemic of obesity and diabetes growing around the world, Kochujang (KCJ) may be potentially effective in preventing and treating obesity and cardiovascular risks if proven in humans. However, human trial still have not been reported with KCJ supplementation. In the present study, we investigated the hypothesis that KCJ supplementation can be decrease the body fat and improve blood lipid profiles in overweight adults.

Detailed Description
-----------------
The aim of this study was to evaluate the efficacy of KCJ supplementation on anthropometric parameters, visceral fat/subcutaneous fat, and blood lipid profiles in overweight subjects. Sixty overweight subjects with BMI >25 kg/m2 and waist-hip-ratio (WHR) ≥ 0.90 for men and ≥ 0.85 for women were randomly assigned to either KCJ supplement (n=30, 32 g/day) or placebo (n=30, 32 g/day) group for 12 weeks.

Official Title
-----------------
Kochujang Decreases Visceral Fat and Improves Lipids Profiles

Conditions
-----------------
Overweight

Intervention / Treatment
-----------------
* Dietary Supplement: Kochujang
* Dietary Supplement: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI >25kg/m2 and 2)Waist-Hip Ratio (WHR): WHR> 0.90(male), WHR>0.85(female) Exclusion Criteria: lipid metabolic disorders >10% changes in body weight in the past 3 months Cardiovascular disease such as arrhythmia, heart failure, myocardial infarction, and wearing pacemaker Allergy or hypersensitivity to any of the ingredients in the test products - History of reaction to any of the experimental products or of gastrointestinal diseases such as Crohn's disease or gastrointestinal surgery Participation in other clinical trials within the past 2 months Abnormal hepatic liver function, renal disease such as acute chronic renal failure, nephrotic syndrome Use of anti-psychosis drug therapy within 2 months Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study History of alcohol or substance abuse Pregnancy or breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Kochujang(32g)<br> | Dietary Supplement: Kochujang<br>* Kochujang (32g/day) for 12weeks.<br>|
| Placebo Comparator: placebo(32g)<br> | Dietary Supplement: placebo<br>* placebo(32g/day) for 12weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visceral fat |  | after 12 weeks of consumption | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body Mass Index |  | after 12 weeks of consumption | 
| Subcutaneous fat |  | after 12weeks | 
| Triglyceride |  | after 12week of consumption | 
| Atherosclerosis index |  | after 12weeks of consumption | 
| Apolipoprotein |  | after 12weeks of consumption | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Kochujang,, visceral fat, population